Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,291 signal articles · 50 in last 24h · 115,510 total before filter · latest 36m ago
50last 24h
1769last 7d
298● bullish (7d)
168● bearish (7d)
205publishers
AllMacro315Earnings818M&A104Regulatory25Product16Analyst26
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year
24/7 Wall St.32d agobullish
The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year

Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year

AI Chips Update - Arteris Arm Partnership Strengthens AI Chip Security
Simply Wall St.32d agobullish
AI Chips Update - Arteris Arm Partnership Strengthens AI Chip Security

In a significant development for the AI chip sector, Arteris, Inc. has announced an expanded partnership with Arm to enhance semiconductor cybersecurity. This alliance builds on a five-year collaboration, utilizing Arteris' Cycuity Radix hardware security assurance product. By integrating Cycuity Radix into Arm's CPU design processes, the partnership aims to proactively address potential security vulnerabilities and strengthen the security assurance of processor cores. This strategic move...

Why Johnson & Johnson Stock Is Falling Even After a Guidance Hike
Barrons.com32d agobullish
Why Johnson & Johnson Stock Is Falling Even After a Guidance Hike

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

Netflix's move to buy Letterboxd sends a key signal to investors
TheStreet32d agobullish
Netflix's move to buy Letterboxd sends a key signal to investors

Netflix (NFLX) spent the past two years defending its lead with price hikes and a password-sharing crackdown. The next phase looks different. The streaming giant is among several companies in early talks to acquire Letterboxd. Letterboxd is a social platform where film fans connect and review ...

3 Reasons GEL is Risky and 1 Stock to Buy Instead
StockStory32d agobullish
3 Reasons GEL is Risky and 1 Stock to Buy Instead

Over the past six months, Genesis Energy’s shares (currently trading at $14.60) have posted a disappointing 14% loss, well below the S&P 500’s 8.2% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.

3 Quality Compounders on Our Buy List
StockStory32d agobullish
3 Quality Compounders on Our Buy List

Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.

3 Market-Beating Stocks with Solid Fundamentals
StockStory32d agobullish
3 Market-Beating Stocks with Solid Fundamentals

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Investing.com32d agobullish
Alibaba shares jump as China clears Apple’s Qwen-powered AI system

Investing.com -- Shares of Alibaba Group in the U.S. rose around 5% in premarket trading after Chinese regulators cleared Apple’s on-device artificial intelligence system for release in the country, a long-delayed approval that pairs the iPhone maker with Alibaba’s Qwen AI model for users in the world’s largest smartphone market.